Bioqual, Inc. (BIOQ)
OTCMKTS · Delayed Price · Currency is USD
37.51
-0.19 (-0.50%)
At close: Feb 6, 2026

Bioqual Company Description

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

The company provides contract research services in the areas of AIDS, influenza, respiratory syncytial virus, Coronavirus, malaria, hepatitis, cancer, and other infectious diseases, as well as flavivirus infections, including zika and dengue.

It also offers small and large animal models. In addition, the company provides cell-based assays, immunoassay, toxicology and cytotoxicity testing, viral load testing, and tailored assay development services; and Biocontainment, imaging services, and animal model development; and IND-enabling services, such as toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation services.

Bioqual, Inc. was incorporated in 1981 and is based in Rockville, Maryland.

Bioqual, Inc.
Bioqual logo
Country United States
Founded 1981
Industry Diagnostics & Research
Sector Healthcare
Employees 113
CEO Mark Lewis

Contact Details

Address:
9620 Medical Center Drive
Rockville, Maryland 20850
United States
Phone 240 404 7654
Website bioqual.com

Stock Details

Ticker Symbol BIOQ
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year June - May
Reporting Currency USD
ISIN Number US09065J1016
SIC Code 8731

Key Executives

Name Position
Dr. Hanne Andersen-Elyard Ph.D. President and Chief Scientific Officer
Charles C. Kirk Jr., CPA Chief Financial Officer
Mitchell L. Franklin Chief Operating Officer and Secretary